High vs. Standard Dose Rifampicin for Effusive Tuberculous Pericarditis

Summary

The investigators hypothesise that high dose RIF (RIF35) will increase pericardial fluid RIF exposure and so enhance mycobacterial clearance, compared to standard of care dosing (RIF10). This Phase 2b randomized, placebo-controlled, double-blinded trial will evaluate the efficacy and safety of RIF 35mg/kg compared 10mg/kg, added to standard first-line ATT, for the treatment of PCTB.

Timeline

Start

2022-01-10

Primary completion

2025-09-15

Completion

2026-02-28

Drugs

Indications